SaNOtize’s NONS Phase 2 study proves efficacy in COVID-19 treatment

By Nikita Chaurasia  Date: 2021-03-16

SaNOtize’s NONS Phase 2 study proves efficacy in COVID-19 treatment

Vancouver-headquartered biotechnology organization, SaNOtize Research & Development Corp has announced the results of its Phase 2 trials of Nitric Oxide Nasal Spray, abbreviated as NONS, for the treatment of patients diagnosed with COVID-19.

For those uninitiated, NONS treatment is based on NO (nitric oxide), a natural nano molecule produced in the human body which exhibits anti-microbial properties and characteristics proven to have a direct effect on the Coronavirus. Moreover, the treatment is designed to kill the virus in the upper airways, barricading its incubation and entry into the lungs.

According to reliable sources, the phase 2 clinical trials indicated that SaNOtize’s NONS is an effective and safe antiviral treatment that prevents the transmission of the coronavirus, shortens its course, and significantly reduces the severity of symptoms in individuals already diagnosed.

SaNOtize has issued a press release stating that the Phase 2 clinical trials found that early treatment of COVID-19 patients with NONS substantially reduced the levels of SARS-CoV-2 coronavirus, including in individuals experiencing high viral loads. Notably, NONS is the only treatment that has proven to reduce viral loads in humans.

If sources are to be believed, the preliminary data comes from a double-blind, placebo-controlled, randomized clinical trial round conducted on 79 confirmed cases of COVID-19. Furthermore, the trials recorded an average viral log of 1.362 in the first 24 hours, which is a decline of around 95%.

This was followed by a 99% drop of the viral load within 72 hours of the commencement of the test, sources confirmed.

Gilly Regev, Co-founder, and CEO of SaNOtize, was reported saying that the biotech company will now focus on efficiently administering the vaccine among the masses and will work towards bringing an end to the ongoing pandemic as well as preventing future outbreaks of relevant viruses.

SaNOtize is currently seeking Emergency Use Authorization from regulatory authorities in Canada and the United Kingdom.

Source credits –

 https://www.businesswire.com/news/home/20210315005197/en/UK-Clinical-Trial-Confirms-SaNOtize%E2%80%99s-Breakthrough-Treatment-for-COVID-19

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...